Hypertriglyceridemia Agents

Elevated plasma triglycerides have been recognized as a metabolic abnormality since the mid-twentieth century, but their clinical significance was debated for decades. Early lipid research focused almost exclusively on cholesterol and its relationship to atherosclerosis, leaving hypertriglyceridemia — defined as fasting triglyceride levels ≥ 150 mg/dL — as a secondary concern. It was not until landmark epidemiologic studies and the advent of fibrate therapy that clinicians began to appreciate triglycerides as an independent contributor to cardiovascular disease (CVD) risk and, at very high levels, a direct trigger for acute pancreatitis. The evolution of triglyceride-lowering pharmacotherapy has spanned fibrates, niacin, omega-3 fatty acids, and newer targeted agents, each reflecting advancing knowledge of lipoprotein metabolism.

This historical arc reveals a central question in cardiovascular pharmacology: how do we most effectively and safely lower triglyceride-rich lipoproteins, and for which patients does this intervention translate into meaningful reductions in pancreatitis and atherosclerotic cardiovascular disease? Answering this question requires a thorough understanding of the mechanisms, clinical indications, and comparative profiles of the agents available today.

Before examining individual drug classes, it is essential to understand the metabolic framework that governs plasma triglyceride levels. Triglycerides circulate in the blood within triglyceride-rich lipoproteins (TRLs), principally chylomicrons (exogenous pathway) and very-low-density lipoproteins (VLDL) (endogenous pathway). The balance between hepatic production and peripheral clearance of these particles determines the fasting and postprandial triglyceride concentration. All pharmacologic interventions target one or both sides of this equation — they either reduce hepatic TRL synthesis and secretion, or enhance peripheral lipolysis and clearance.

The diagram above illustrates why a single-target approach may not suffice for all patients. In familial chylomicronemia syndrome (FCS), for instance, LPL is genetically absent or nonfunctional, rendering fibrates and standard omega-3 therapy largely ineffective. In such cases, apoC-III antisense oligonucleotides offer a mechanism-specific advantage by promoting LPL-independent hepatic uptake of TRL remnants. Clinically, the choice of agent depends on the underlying pathophysiology, the severity of hypertriglyceridemia, and the concurrent cardiovascular risk profile.

Fibrates — PPARα Agonists

Fibrates — including gemfibrozil and fenofibrate — are synthetic ligands for the nuclear transcription factor peroxisome proliferator-activated receptor alpha (PPARα). Activation of PPARα in hepatocytes and skeletal muscle upregulates genes encoding lipoprotein lipase, apolipoprotein A-I (apoA-I), apoA-II, and fatty acid transport proteins, while simultaneously downregulating apoC-III expression. The net pharmacodynamic effects include a 20–50% reduction in triglycerides, a 5–20% increase in HDL-cholesterol, and a variable (usually modest) change in LDL-cholesterol. A critical drug interaction exists between gemfibrozil and statins: gemfibrozil inhibits the glucuronidation of statins via UGT enzymes, markedly increasing the risk of myopathy and rhabdomyolysis. Fenofibrate is preferred when combination therapy with a statin is necessary because it does not share this interaction.

Omega-3 Fatty Acids

Prescription omega-3 formulations contain eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA). These long-chain polyunsaturated fatty acids reduce VLDL-TG secretion through multiple mechanisms: they serve as poor substrates for diacylglycerol acyltransferase (DGAT) and phosphatidic acid phosphatase, enhance peroxisomal and mitochondrial β-oxidation of fatty acids, and activate PPARα. Icosapent ethyl (purified EPA ethyl ester) is distinguished from mixed EPA/DHA products by its demonstrated cardiovascular outcome benefit in the REDUCE-IT trial. EPA-only formulations do not raise LDL-cholesterol, whereas DHA-containing products may modestly increase LDL-C. Triglyceride reductions of 20–45% are typical at prescription doses (2–4 g/day).

Niacin (Nicotinic Acid)

Niacin (vitamin B₃) at pharmacologic doses (1–3 g/day) inhibits hormone-sensitive lipase in adipose tissue via the GPR109A (HM74A) receptor, reducing free fatty acid flux to the liver and subsequently decreasing hepatic VLDL-TG synthesis. Niacin also inhibits hepatic DGAT-2 directly. It is the most potent available agent for raising HDL-cholesterol (15–35% increase) and produces triglyceride reductions of 20–50%. However, the AIM-HIGH and HPS2-THRIVE trials showed no incremental cardiovascular benefit when niacin was added to statin therapy, and its significant side effects — prostaglandin-mediated flushing, hepatotoxicity, hyperglycemia, and hyperuricemia — have relegated it to a minor role in current guidelines.

ApoC-III and ANGPTL3 Inhibitors

Volanesorsen is an antisense oligonucleotide (ASO) that binds apoC-III mRNA in hepatocytes, triggering RNase H-mediated degradation and reducing circulating apoC-III protein by approximately 70–80%. Since apoC-III normally inhibits LPL and impairs hepatic remnant receptor uptake, its suppression produces dramatic triglyceride reductions of 50–80%, even in patients with familial chylomicronemia syndrome (FCS). Thrombocytopenia is a notable adverse effect requiring monitoring. Evinacumab, a fully human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), disinhibits both LPL and endothelial lipase, lowering triglycerides, LDL-C, and HDL-C in an LDL receptor-independent manner. Although primarily approved for homozygous familial hypercholesterolemia, its TG-lowering properties are being explored in severe hypertriglyceridemia.

When selecting an agent, clinicians consider the severity of hypertriglyceridemia, the underlying etiology, concurrent medications, and the patient's cardiovascular risk profile. For patients with triglycerides ≥ 500 mg/dL, the primary goal is pancreatitis prevention, and fibrates or omega-3 fatty acids are first-line. For patients with moderate hypertriglyceridemia (150–499 mg/dL) who are already on statin therapy and have established cardiovascular disease, icosapent ethyl is the only agent with Level 1 evidence for reducing major adverse cardiovascular events (MACE).

The field of triglyceride pharmacology is evolving rapidly, driven by genetic insights from Mendelian randomization studies and genome-wide association studies (GWAS) that have validated novel targets. Loss-of-function variants in APOC3, ANGPTL3, and ANGPTL4 genes are associated with lower triglycerides and reduced cardiovascular risk, providing a genetic "proof of concept" for pharmacologic inhibition of these targets. This paradigm, sometimes called "nature's clinical trial," has accelerated drug development beyond traditional small-molecule approaches into the realm of RNA therapeutics and biologic agents.

Looking forward, several agents in late-phase development merit attention. Olezarsen is a next-generation GalNAc-conjugated antisense oligonucleotide targeting apoC-III with improved hepatocyte specificity and reduced thrombocytopenia risk compared to volanesorsen. Phase 3 trials (BALANCE, BRIDGE-TIMI 73a) have shown robust triglyceride reductions and favorable safety profiles. Meanwhile, pemafibrate, a selective PPARα modulator (SPPARMα), was designed to retain fibrate efficacy while reducing off-target adverse effects; however, the PROMINENT trial showed no MACE benefit in diabetic patients, casting doubt on the triglyceride-lowering hypothesis for CVD reduction when the mechanism is PPARα-mediated alone. These developments underscore that mechanism of triglyceride lowering — not just the magnitude — may determine cardiovascular benefit.